Loading
A phase 1 trial of CID-078 run by Circle Pharma, active and no longer recruiting.
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies is a phase 1 interventional study registered as NCT06577987 by Circle Pharma, with 220 participants planned, started 2024-08-14. Conditions recorded: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma and RB1 Gene Mutation. Interventions recorded: CID-078 Monotherapy.
Shares Breast cancer (all types), Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lung cancer (all types), Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lung cancer (all types), Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lung cancer (all types), Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lung cancer (all types), Breast cancer (all types) and the tag pipeline.
Shares Neuroendocrine tumours, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/